Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

SIMPL Is a Tumor Necrosis Factor-specific Regulator of Nuclear Factor-B Activity*

Posted by on in 2001
  • Font size: Larger Smaller
  • Hits: 1804
  • Print

Vig, Eva, Melissa Green, Yuanwen Liu, Kang-Yeol Yu, Hyung-Joo Kwon, Jun Tian, Mark G. Goebl, and Maureen A. Harrington, 2001, J. Biol. Chem., 276 (11):7859-7866.

From the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine and the Walther Cancer Institute, Indianapolis, Indiana 46202-5121


The IL-1 receptor-associated kinase (IRAK/mPLK) is linked to the regulation of nuclear factor-B (NF-B)-dependent gene expression. Here we describe a novel binding partner of IRAK/mPLK that we term SIMPL (signaling molecule that associates with the mouse pelle-like kinase). Overexpression of SIMPL leads to the activation of NF-B-dependent promoters, and inactivation of SIMPL inhibits IRAK/mPLK as well as tumor necrosis factor receptor type I-induced NF-B activity. Dominant inhibitory alleles of IB kinase (IKK or IKK) block the activation of NF-B by IRAK/mPLK and SIMPL. Furthermore, SIMPL binds IRAK/mPLK and the IKKs in vitro and in vivo. In the presence of antisense mRNA to SIMPL, the physical association between IRAK/mPLK and IKK but not IRAK/mPLK and IKK is greatly diminished. Moreover, dominant-negative SIMPL blocks IKK- or IKK-induced NF-B activity. These results lead us to propose a model in which SIMPL functions to regulate NF-B activity by linking IRAK/mPLK to IKK/-containing complexes.

*Custom peptides and IgY antibodies used in this publication were produced by Gallus Immunotech Inc. Please visit our Custom Peptide Synthesis and Custom IgY Production  pages for more information.

Last modified on